

SUPPLEMENTARY TABLE 2. Estimated vaccination coverage with selected vaccines and doses among adolescents* aged 13–17 years by poverty level† — National Immunization Survey–Teen (NIS-Teen), United States, 2018.

Vaccines	Poverty Status, % (95% CI) [§]		
	Below Poverty Level	At or Above Poverty Level	Difference for Below minus At or Above Poverty
	(n=3,327)	(n=14,716)	(n= 18,043)
Tdap[¶] ≥1 dose	87.5 (85.4 to 89.4)	89.2 (88.3 to 90.1)	-1.7 (-3.9 to 0.5)
MenACWY ^{**}			
≥1 dose	86.2 (83.8 to 88.3)	86.6 (85.6 to 87.6)	-0.4 (-2.9 to 2.1)
≥2 doses ^{††}	48.2 (41.1 to 55.4)	51.5 (48.1 to 55.0)	-3.3 (-11.3 to 4.7)
HPV^{§§} vaccine			
≥1 dose	76.2 (73.5 to 78.7) ^{¶¶}	65.8 (64.4 to 67.2)	10.4 (7.4 to 13.4) ^{¶¶}
HPV UTD ^{***}	57.1 (53.9 to 60.2) ^{¶¶}	49.6 (48.1 to 51.1)	7.5 (4.0 to 11.0) ^{¶¶}
≥2 MMR doses	91.6 (89.8 to 93.1)	92.2 (91.5 to 93.0)	-0.7 (-2.5 to 1.2)
≥3 Hepatitis B doses	91.3 (89.4 to 93.0)	92.6 (91.7 to 93.3)	-1.2 (-3.2 to 0.7)
Varicella			
History of varicella disease ^{†††}	15.7 (13.4 to 18.4) ^{¶¶}	10.6 (9.7 to 11.5)	5.1 (2.5 to 7.8) ^{¶¶}
No history of varicella disease			
≥1 dose vaccine	94.0 (92.0 to 95.5)	95.1 (94.5 to 95.7)	-1.1 (-3.0 to 0.7)
≥2 doses vaccine	89.2 (87.0 to 91.1)	89.9 (88.9 to 90.9)	-0.7 (-3.0 to 1.6)
History of varicella or received ≥2 doses varicella vaccine	90.9 (89.0 to 92.5)	91.0 (90.1 to 91.8)	-0.1 (-2.0 to 1.9)

Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up-to-date.

* Adolescents (N = 18,700) in the 2018 NIS-Teen were born January 2000 through February 2006.

† Adolescents were classified as below poverty level if their total family income was less than the federal poverty level specified for the applicable family size and number of children aged <18 years. All others were classified as at or above the poverty level. Additional information available at <https://www.census.gov/data/tables/time-series/demo/income-poverty/historical-poverty-thresholds.html>. Poverty status was unknown for (N = 657) adolescents.

§ Estimates with 95% confidence intervals > 20 may not be reliable.

¶ Includes percentages receiving Tdap vaccine at age ≥10 years.

** Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.

†† ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.

§§ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV).

¶¶ Statistically significant difference (p<0.05) in estimated vaccination coverage by poverty level; referent groups was adolescents living at or above poverty level.

*** HPV UTD includes those with ≥ 3 doses and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was at least five months minus four days between the first and second dose.

††† By parent/guardian report or provider records.